Wang Mei, Gu Jun, Wang Hai-Xing, Wu Mei-Hong, Li Yong-Mei, Wang Ya-Jie
Oncology Department, Changhai hospital, Shanghai, China.
Asian Pac J Cancer Prev. 2012;13(8):4153-6. doi: 10.7314/apjcp.2012.13.8.4153.
To investigate the efficacy and toxicity of a combination of gemcitabine with nedaplatin (GN) or cisplatin (GC) for patients with unresectable or recurrent esophagus squamous cell carcinoma.
Gemcitabine was administered at 1 g/m2 intravenously on days 1 and 8; and nedaplatin or cisplatin were administered at 80 mg/m2 intravenously on day 1. We analyzed the response rate, overall survival time, progression-free survival time, and toxicity in 21 patients treated with GN and 27 patients treated with GC.
In patients treated with gemcitabine plus nedaplatin, the ORR was 47.6%, the median progression-free survival time was 4.1 months, and the median survival time was 9.3 months. In patients treated with gemcitabine plus cisplatin, the ORR was 48.2%, the median progression-free survival time was 3.9 months, and the median survival time was 9.1 months, respectively. There were no statistically significant differences in ORR, PFS and OS between the two groups. In both, the most commonly observed toxicities were thrombocytopenia and fatigue. Nausea and vomiting was more frequent in the GC group than in the GN group.
Gemcitabine based chemotherapy was effective and tolerable for patients with unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.
探讨吉西他滨联合奈达铂（GN）或顺铂（GC）治疗不可切除或复发食管鳞状细胞癌患者的疗效和毒性。
吉西他滨在第1天和第8天静脉滴注，剂量为1 g/m²；奈达铂或顺铂在第1天静脉滴注，剂量为80 mg/m²。我们分析了21例接受GN治疗的患者和27例接受GC治疗的患者的缓解率、总生存时间、无进展生存时间和毒性。
吉西他滨联合奈达铂治疗的患者，客观缓解率（ORR）为47.6%，中位无进展生存时间为4.1个月，中位生存时间为9.3个月。吉西他滨联合顺铂治疗的患者，ORR为48.2%，中位无进展生存时间为3.9个月，中位生存时间为9.1个月。两组之间的ORR、无进展生存期（PFS）和总生存期（OS）无统计学显著差异。两者中最常见的毒性反应是血小板减少和疲劳。GC组恶心和呕吐比GN组更频繁。
对于一线化疗难治的不可切除或复发食管鳞状细胞癌患者，以吉西他滨为基础的化疗有效且耐受性良好。
